Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint - Related Studies

Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint

This study has been terminated.

Study NCT00613730. Last updated on February 20, 2008. Information provided by Amgen

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cancer of Pancreas
		Cancer of the Pancreas
		Pancreas Cancer
		Pancreatic Cancer

2	Additional conditions recognized in this trial
		Adenocarcinoma
		Pancreatic Neoplasms

3	More general conditions related to this trial
		Carcinoma
		Digestive System Diseases
		Digestive System Neoplasms
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Pancreatic Diseases

4	Interventions listed in this trial
		Gemcitabine
		panitumumab

5	More general drug interventions related to this trial
		Anti-Infective Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antiviral Agents
		Enzyme Inhibitors
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

6	Sponsors listed in this trial
		Amgen